TARS News and Press, Tarsus Pharmaceuticals Inc. From 07/26/21

Yuliya Starikova/iStock via Getty Images Tarsus Pharmaceuticals (TARS) announces new data from its Saturn-1 Phase 2b/3 trial and the Titan real-world collarette prevalence study at the ASCRS 2021 Annual Meeting. The new Saturn-1 data reinforce the strong potential clinical utility of TP-03 (l...

New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade Further Saturn-1 safety analysis revealed that TP-03 had a favorable...

IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care...

Tarsus Pharmaceuticals (NASDAQ: TARS) , Anavex Life Sciences (NASDAQ: AVXL) , and MediciNova (NASDAQ: MNOV) all had recent positive news coming out of phase 2 clinical trials that should whet investors' appetites. Investing in a stock based mainly on a solid phas...

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care...

Gainers: Lydall (LDL) +85%.Raven Industries (RAVN) +50%.Torchlight Energy Resources (TRCH) +45%.Alset EHome International (AEI) +39%.Globalstar (GSAT) +20%.ContextLogic (WISH) +19%.1847 Goedeker (GOED) +19%.Smith & Wesson Brands (SWBI) +17%.Anavex Life Sciences (AVXL) +17%....

Gainers: Virpax Pharmaceuticals (VRPX) +16%, Anavex Life Sciences AVXL +15%, MediciNova MNOV +14%, Aytu Biopharma (AYTU) +14%, Applied Molecular Transport (AMTI) +8%.Losers: Aptevo Therapeutics (APVO) -18%, Intec Pharma (NTEC) -16%, Conformis ...

Tarsus Pharmaceuticals (TARS) soars 15% premarket after announcing that all pre-specified primary and secondary endpoints were met for its Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis.Demodex blepharitis is c...

Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related discontinuations, demonstrating the potential of TP-03 to treat Demodex blepharitis, a ...

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care...